Royal Bank Of Canada Forecasts Strong Price Appreciation for Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) had its target price boosted by Royal Bank Of Canada from $180.00 to $190.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “sector perform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 3.18% from the stock’s previous close.

BDX has been the topic of a number of other reports. Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Stock Up 0.3%

Shares of BDX traded up $0.57 during trading hours on Thursday, hitting $184.15. The stock had a trading volume of 245,511 shares, compared to its average volume of 2,678,070. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a market capitalization of $50.74 billion, a P/E ratio of 55.38, a price-to-earnings-growth ratio of 12.79 and a beta of 0.19. The firm has a 50 day simple moving average of $156.55 and a 200-day simple moving average of $161.69. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business earned $3.68 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 7,627 shares of company stock worth $1,206,549. Corporate insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently added to or reduced their stakes in BDX. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the last quarter. United Bank grew its holdings in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after purchasing an additional 993 shares during the last quarter. Marshall Wace LLP raised its position in Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.